Molecular and Medical Aspects of Psychedelics
- PMID: 38203411
- PMCID: PMC10778977
- DOI: 10.3390/ijms25010241
Molecular and Medical Aspects of Psychedelics
Abstract
Psychedelics belong to the oldest psychoactive drugs. They arouse recent interest due to their therapeutic applications in the treatment of major depressive disorder, substance use disorder, end-of-life anxiety,= and anxiety symptoms, and obsessive-compulsive disorder. In this review, the current state of preclinical research on the mechanism of action, neurotoxicity, and behavioral impact of psychedelics is summarized. The effect of selective 5-HT2A receptor agonists, 25I- and 25B-NBOMe, after acute and repeated administration is characterized and compared with the effects of a less selective drug, psilocybin. The data show a significant effect of NBOMes on glutamatergic, dopaminergic, serotonergic, and cholinergic neurotransmission in the frontal cortex, striatum, and nucleus accumbens. The increases in extracellular levels of neurotransmitters were not dose-dependent, which most likely resulted from the stimulation of the 5-HT2A receptor and subsequent activation of the 5-HT2C receptors. This effect was also observed in the wet dog shake test and locomotor activity. Chronic administration of NBOMes elicited rapid development of tolerance, genotoxicity, and activation of microglia. Acute treatment with psilocybin affected monoaminergic and aminoacidic neurotransmitters in the frontal cortex, nucleus accumbens, and hippocampus but not in the amygdala. Psilocybin exhibited anxiolytic properties resulting from intensification of GABAergic neurotransmission. The data indicate that NBOMes as selective 5-HT2A agonists exert a significant effect on neurotransmission and behavior of rats while also inducing oxidative DNA damage. In contrast to NBOMes, the effects induced by psilocybin suggest a broader therapeutic index of this drug.
Keywords: behavior; neurotransmitter release; psychedelics; receptors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10778977/bin/ijms-25-00241-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10778977/bin/ijms-25-00241-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10778977/bin/ijms-25-00241-g003.gif)
Similar articles
-
[Contribution of serotonin 5-HT2A receptor to antidepressant effect of serotonergic psychedelics].Nihon Yakurigaku Zasshi. 2023 May 1;158(3):229-232. doi: 10.1254/fpj.22141. Epub 2023 Mar 29. Nihon Yakurigaku Zasshi. 2023. PMID: 36990794 Review. Japanese.
-
Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3019-3035. doi: 10.1007/s00210-023-02778-x. Epub 2023 Oct 24. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37874338
-
Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?Neuropsychopharmacology. 2024 Mar;49(4):747-756. doi: 10.1038/s41386-024-01794-6. Epub 2024 Jan 11. Neuropsychopharmacology. 2024. PMID: 38212441 Free PMC article.
-
[Up-to-Date on clinical and preclinical studies of psilocybin therapy].Nihon Yakurigaku Zasshi. 2024;159(4):214-218. doi: 10.1254/fpj.24007. Nihon Yakurigaku Zasshi. 2024. PMID: 38945903 Review. Japanese.
-
Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe.Psychopharmacology (Berl). 2021 Aug;238(8):2349-2364. doi: 10.1007/s00213-021-05860-5. Epub 2021 May 25. Psychopharmacology (Berl). 2021. PMID: 34032876 Free PMC article.
Cited by
-
Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies.J Neural Transm (Vienna). 2024 May;131(5):525-561. doi: 10.1007/s00702-024-02757-3. Epub 2024 Mar 30. J Neural Transm (Vienna). 2024. PMID: 38554193 Review.
References
-
- Schultes R.E., Hofmann A., Rätsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Heal. Art. Press. 1998:1–208. doi: 10.2307/2806799. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources